Amedica and K2M Ink Distribution Deal in Europe

Amedica Corp. has signed a distribution deal with K2M Inc. that will provide surgeons and hospitals in Europe with access to Amedica’s interbody spinal fusion devices made with silicon nitride.

Earlier this year, Amedica and K2M conducted a successful pilot program in select markets in Europe where surgeons were provided the opportunity to integrate silicon nitride interbody devices into their offerings for patients suffering from a variety of disorders requiring spinal fusion. According to the companies, the program demonstrated a need in these strategic markets for spinal fusion devices devised from a different biomaterial.

“K2M is committed to providing the best and most innovative technologies to meet the needs of patients around the world suffering from spinal disorders and we believe our relationship with Amedica will help us further this goal,” said Eric Major, K2M’s president and CEO. “We are thrilled to make Amedica’s silicon nitride interbody spinal fusion devices part of our comprehensive international product portfolio.”

“K2M has an outstanding sales and marketing team that has created a global reputation for providing leading-edge technology to their customers. Our silicon nitride interbody product line will be integrated into K2M’s current portfolio of interbody spinal fusion devices,” said Eric K. Olson, president and CEO, Amedica. “We believe it is evident that there is a need in Europe for interbody fusion devices that exceed the capabilities of existing PEEK and titanium-based devices. With this distribution channel in place, we believe Silicon Nitride interbody spinal fusion devices will increasingly be the solution that surgeons rely on to deliver optimal patient outcomes in spinal fusion procedures.”

Salt Lake City, Utah-based Amedica is a biomaterial company that uses its silicon nitride technology platform to develop and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing products for use in total hip and knee joint replacements.

K2M claims to be the largest privately held spinal device company in the world. The company makes technology for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes spinal stabilization systems, minimally invasive systems, biologics, and other technologies, such as motion preservation, annular repair and nucleus replacement.